INTRODUCTION {#s1}
============

Inactivating *CDK12* alterations have been reported in ovarian and prostate cancers; however, the prevalence of these mutations across all cancer types is unknown \[[@R1]\]. While *CDK12* was initially thought to be involved in homologous-recombination DNA repair, emerging data suggest a unique role of this gene in DNA replication-associated repair. To this end, it has been suggested that inactivating *CDK12* mutations lead to widespread focal genomic duplications that generate gene fusion-induced neoantigens and favorable responses to immune-checkpoint blockade therapy using PD-1 inhibitors \[[@R2]\]. Given this potentially actionable molecular subtype, we sought to determine the prevalence of monoallelic and biallelic *CDK12* alterations across tumor types.

RESULTS {#s2}
=======

Datasets (in cBioPortal and GENIE) from prostate, breast, colorectal, bladder, ovarian, uterine, head-and-neck squamous cell carcinoma, melanoma, and esophago-gastric cancers were included (Table [1](#T1){ref-type="table"}); other tumor types did not reach a 1% frequency of *CDK12* alterations. The prevalence of at least monoallelic *CDK12* mutations was highest in bladder cancer (3.7%); followed by prostate (3.4%), esophago-gastric (2.1%) and uterine cancers (2.1%). Biallelic *CDK12* inactivation was highest in prostate cancer (1.8%), followed by ovarian (1.0%) and bladder cancers (0.5%) (Figure [1](#F1){ref-type="fig"}).

###### Datasets publically available from cBioPortal and GENIE Project that were used, by disease group, with overall sample size

  Disease                        Dataset                        Sample Size   Total
  ------------------------------ ------------------------------ ------------- --------
  **Bladder**                    BLCA_TCGA_PAN_CAN_ATLAS_2018   408           1,181
  DFCI-ONCOPANEL-3               69                                           
  MSK-IMPACT341                  95                                           
  MSK-IMPACT410                  326                                          
  MSK-IMPACT468                  143                                          
  UTUC_MSKCC_2013                84                                           
  VICC-01-T5A                    3                                            
  VICC-01-T7                     53                                           
  **Breast**                     BRCA_IGR_2015                  216           3,442
  BRCA_MBCPROJECT_WAGLE_2017     157                                          
  DFCI-ONCOPANEL-3               304                                          
  MSK-IMPACT341                  410                                          
  MSK-IMPACT410                  1,021                                        
  MSK-IMPACT468                  1,076                                        
  VICC-01-T5A                    87                                           
  VICC-01-T7                     171                                          
  **Colorectal**                 CRC_MSK_2018                   1,134         3,272
  DFCI-ONCOPANEL-3               351                                          
  MSK-IMPACT341                  209                                          
  MSK-IMPACT410                  906                                          
  MSK-IMPACT468                  465                                          
  VICC-01-T5A                    47                                           
  VICC-01-T7                     160                                          
  **Esophagogastric**            DFCI-ONCOPANEL-3               146           1,458
  EGC_MSK_2017                   341                                          
  ESCA_TCGA_PAN_CAN_ATLAS_2018   182                                          
  MSK-IMPACT341                  122                                          
  MSK-IMPACT410                  216                                          
  MSK-IMPACT468                  106                                          
  STES_TCGA_PUB                  288                                          
  VICC-01-T5A                    11                                           
  VICC-01-T7                     46                                           
  **HNSCC**                      DFCI-ONCOPANEL-3               83            1, 010
  HNC_MSKCC_2016                 151                                          
  HNSC_TCGA_PAN_CAN_ATLAS_2018   517                                          
  MSK-IMPACT341                  37                                           
  MSK-IMPACT410                  132                                          
  MSK-IMPACT468                  75                                           
  VICC-01-T5A                    6                                            
  VICC-01-T7                     9                                            
  **Melanoma**                                                                906
  MSK-IMPACT341                  64                                           
  MSK-IMPACT410                  364                                          
  MSK-IMPACT468                  214                                          
  VICC-01-T7                     140                                          
  VICC-01-T5A                    37                                           
  **Ovarian**                    DFCI-ONCOPANEL-3               125           1,065
  MSK-IMPACT341                  88                                           
  MSK-IMPACT410                  139                                          
  MSK-IMPACT468                  155                                          
  OV_TCGA_PUB                    489                                          
  VICC-01-T5A                    31                                           
  VICC-01-T7                     38                                           
  **Prostate**                   DFCI-ONCOPANEL-3               97            2,251
  MSK-IMPACT341                  153                                          
  MSK-IMPACT410                  569                                          
  MSK-IMPACT468                  377                                          
  PRAD_FHCRC                     149                                          
  PRAD_MICH                      61                                           
  PRAD_MSKCC                     194                                          
  PRAD_SU2C_2015                 150                                          
  PRAD_MSKCC_2017                501                                          
  **Uterine**                    DFCI-ONCOPANEL-3               120           1,085
  MSK-IMPACT341                  119                                          
  MSK-IMPACT410                  258                                          
  MSK-IMPACT468                  326                                          
  UCEC_TCGA_PUB                  232                                          
  VICC-01-T7                     19                                           
  VICC-01-T5A                    11                                           
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DISCUSSION {#s3}
==========

In the era of precision oncology, inactivation of *CDK12* may represent a new molecular subtype with therapeutic implications \[[@R6]\], although the pan-cancer prevalence of this genomic alteration was previously unknown. These results are the first (to our knowledge) to estimate the prevalence of monoallelic and biallelic *CDK12* mutations across nine cancer types encompassing \>15,000 cases. This is important as *CDK12* alterations may be implicated in favorable responses to immune checkpoint inhibition, with biallelic alterations theoretically expected to respond better than monoallelic alterations. Prospective clinical trials (e.g. NCT03570619) are now needed to adequately assess this therapeutic hypothesis, and our data could be useful in the design of such trials.

Our results are limited to data that were publicly available. In addition, genotyping and mutation calling are sensitive to several factors, *e.g.* quality of the sample, sequencing depth and platform, and the pipeline used. Additionally, datasets from the GENIE Project revealed overall lower *CDK12* mutation rates than datasets retrieved from cBioPortal. The reason for this is unclear but may include different pipelines with different sensitivity and specificity, artifacts due to DNA damage in sample preparation found in the capture-panels used in the GENIE Project, and differing sample quality (all samples from the GENIE Project were formalin-fixed paraffin-embedded while most from cBioPortal were fresh-frozen samples) \[[@R3]--[@R5]\]. Because of this, we hypothesize that our reported prevalences are likely underestimates of the true frequency of these mutations. Nevertheless, our analysis suggests that there are at least nine cancer types with a *CDK12* mutation prevalence between 1-4%, hopefully prompting further exploration of immunotherapy approaches using a basket-trial design. Given the recent FDA-approval of larotrectinib for *NTRK*-altered cancers regardless of histologic type, we envision a similar mode of clinical exploration for *CDK12*-altered tumors.

METHODS {#s4}
=======

We searched the cBioPortal \[[@R3],[@R4]\] and GENIE Project (public release v4.1) \[[@R5]\] databases for cancer types with ≥200 sequenced cases, that included patients with metastatic disease, and in which the prevalence of at least monoallelic *CDK12* alterations was ≥1%. Analyses were restricted to datasets containing both *CDK12* mutation and copy-number alteration (CNA) data using hybridization-capture panels from Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center and Vanderbilt-Ingram Cancer Center. *CDK12* mutations were considered inactivating (i.e. resulting in loss-of-function) in the case of homozygous loss, genomic rearrangements, frameshift or nonsense protein-truncating mutations, splice-site mutations, or missense mutations within the kinase domain. Monoallelic alterations were defined as at least one protein-truncating *CDK12* variant; biallelic alterations were defined as a protein-truncating variant plus a second protein-truncating variant, a kinase domain missense variant, or loss-of-heterozygosity of the wild-type *CDK12* allele. All analyses were performed in R.
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